🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06784479
Active, not recruiting Phase 4

Combination of Remimazolam and Propofol During Drug-induced Sleep Endoscopy

NCT06784479 · tracked via the Priya Life Science China tracker
Sponsor
Dan Liu
Phase
Phase 4
Started
2025-03-01
Last updated
2026-02-24

Condition(s) studied

Sedative Effect During Drug-induced Sleep EndoscopyObstructive Sleep Apnea (OSA)

Investigational drug(s) / intervention(s)

Remimazolam and PropofolPropofolMidazolam and propofol

Remimazolam and Propofol: Application of Remimazolam and Propofol to induce sleep

Propofol: Application of Propofol to induce sleep

Midazolam and propofol: Application of Midazolam and Propofol to induce sleep

Study summary

This study helps patients find the optimal sedation regimen in drug-induced sleep endoscopy

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with sleep apnea hypopnea syndrome were included Exclusion Criteria: * Patients were excluded if they had nasal obstruction, significantly deviated nasal septum, nasal turbinate hypertrophy, or nasal polyps. Patients with uncontrolled heart failure, renal insufficiency, diabetes, or hyperthyroidism were also excluded. Patients were also excluded if taking medications that could affect upper airway muscle function, such as ben- zodiazepines and muscle relaxants.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Respiratory Endoscopy Center of Tianjin Medical University General Hospital Tianjin Tianjin Municipality

More Dan Liu trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06784479 on ClinicalTrials.gov ↗ ← All trials in China